On November 11, GeLongHui|Changjiang Securities research reports suggest that imeik technology development (300896.SZ) is expected to see a slowdown in quarterly revenue growth in 2024 Q3 due to end-demand, but overall it still maintains good profitability. Overall, the company has kept the relative stability of operating profit margin, with a quarterly growth rate of around 2% in net income attributable to shareholders, slightly faster than the revenue growth rate. Currently, the company's Hi series products have established a strong consumer mindshare, and are expected to continue to benefit from the ongoing trend of light medical beauty consumption and the trend of operating compliance. Additionally, the combined application of Ru Bai Angel and Ru Sheng Angel is expected to continue to solidify the high-end price range, while the rich pipeline layout for various indications and product categories lays the foundation for long-term growth. It is estimated that the company's EPS for 2024-2026 will be 6.87, 7.91, and 9.17 yuan respectively, maintaining a "buy" rating.
研报掘金丨长江证券：爱美客三季度保持较好盈利能力，维持“买入”评级
Research reports dig deep into the third quarter, with imeik technology development maintaining good profitability and maintaining a "buy" rating.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.